Navigation Links
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Date:2/20/2009

BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Announces Issuance of U.S. Patent for ITMN-191
2. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
3. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Release Third Quarter 2008 Financial Results on November 6
8. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
9. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. InterMune to Present at Canaccord Adams Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... ... , ... It wasn’t just the San Diego temps that soared this summer. ... has had a record-breaking number of guests for corporate cooking challenges, team events and ... company outings, family get-togethers, anniversaries and milestone birthdays. While all groups gathered in ...
(Date:9/12/2017)... ... 2017 , ... September 15, 2017. Pittsburgh, PA. The ... the Department of Surgery and Cancer and Director of the MRC-NIHR National Phenome ... His presentation, “Analytical Science in Precision Medicine: Facing the Challenges of the 21st ...
(Date:9/12/2017)... ... 2017 , ... Facet Life Sciences, a leading provider of development solutions (software ... PhD has joined the company’s Board of Directors. , Dr. Massa brings 38 ... Most recently he served as VP and Head of Global Regulatory Operations at Sanofi. ...
(Date:9/12/2017)... ... September 11, 2017 , ... As part of BD’s ... BD is sponsoring an educational webinar in recognition of World Sepsis Day ... estimated five million deaths annually, is preventable and treatable through increased awareness and ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):